Antidepressants, cognitive behavioral therapy appear equally effective in treating social phobia

October 04, 2004

CHICAGO - The use of fluoxetine (an antidepressant) or comprehensive cognitive behavioral therapy (CCBT) were similarly effective for treating social phobia, while combining these treatments did not provide further benefit, according to an article in the October issue of The Archives of General Psychiatry, one of the JAMA/Archives journals.

According to the article, as many as 14 percent of people in the United States experience social phobia, also known as social anxiety disorder. Previous studies have shown that selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral treatments (CBTs) have been effective in treating social phobia.

Jonathan R.T. Davidson, M.D., from Duke University Medical Center at Durham, N.C., and colleagues compared the efficacy of fluoxetine, CCBT, placebo, CCBT plus fluoxetine, and CCBT plus placebo in 295 patients with generalized social phobia. Of the study participants, 156 were male and 226 (76.3 percent) were white, with an average age of 37.1 years. Treatment lasted for 14 weeks, with fluoxetine and placebo administered in 10 mg/day to 60 mg/day doses. Those receiving group CCBT attended sessions one day a week for the 14 weeks. The sessions included specific social skills training (for example, how to begin a conversation with a stranger), role playing, and cognitive restructuring.

By the end of the study period, 54.2 percent of those receiving both fluoxetine and CCBT reported "very much improvement" or "much improvement" in their social phobia. Of participants taking only fluoxetine, 50.9 percent reported such progress, while 51.7 percent of participants receiving only CCBT also reported very much or much improvement. A comparable proportion (50.8 percent) of those receiving the combination of CCBT and placebo reported similar results, whereas only 31.7 percent of those who received placebo reported such improvement.

"All active treatments were superior to placebo on primary outcomes. Combined treatment did not yield any further advantage. Notwithstanding the benefits of treatment, many patients remained symptomatic after 14 weeks," the authors write.

"...this [trial] has demonstrated that widely used treatments (i.e., CBT and fluoxetine) are effective for individuals with generalized social phobia, many of whom are significantly impaired. Although fluoxetine and CCBT were more successful than placebo, substantial symptoms still remained after 14 weeks' treatment....Finally, combining fluoxetine with CCBT did not provide any greater therapeutic benefit."
-end-
(Arch Gen Psychiatry. 2004; 61: 1005-1013. Available post-embargo at www.archgenpsychiatry.com)

Editor's note: This study was supported by a grant from the National Institute of Mental Health, Bethesda, Md. (Drs. Davidson and Foa).

For more information, contact JAMA/Archives Media Relations at 312-464-JAMA (5262) or e-mail mediarelations@jama-archives.org.

The JAMA Network Journals

Related Placebo Articles from Brightsurf:

Effect of fluvoxamine vs placebo on clinical deterioration in outpatients with symptomatic COVID-19
This randomized trial compares the effects of fluvoxamine, a selective serotonin reuptake inhibitor with immunomodulatory effects, versus placebo on a composite of dyspnea or pneumonia and oxygen desaturation among adult outpatients with polymerase chain reaction-confirmed mild COVID-19 illness.

Hydroxychloroquine no more effective than placebo in preventing COVID-19
Clinical trial with COVID-19 testing of participants shows health care workers in contact with coronavirus patients who took hydroxychloroquine each day did not reduce their rate of infection.

Compared to placebo, vitamin D has no benefit for severe asthma attacks
Contrary to earlier observational results, vitamin D supplements do not prevent severe asthma attacks in at-risk children, according to the first placebo-controlled clinical trial to test this relationship.

UMN trial shows hydroxychloroquine has no benefit over placebo in preventing COVID-19
Today, University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19.

The placebo effect and psychedelic drugs: tripping on nothing?
A new study from McGill suggests that, in the right context, some people may experience psychedelic-like effects from placebos alone.

Methotrexate reduces joint damage progression over placebo in erosive hand OA
According to new research findings presented at the 2019 ACR/ARP Annual Meeting, methotrexate did not demonstrate superior efficacy over placebo for pain relief and function evolution at three and 12 months in patients with erosive hand osteoarthritis, but did significantly reduce the progression of joint damage over placebo and seems to facilitate bone remodeling in these patients.

Botulinum toxin reduces chronic migraine attacks, compared to placebo
A growing body of evidence supports the effectiveness of botulinum toxin injections in reducing the frequency of chronic migraine headaches, concludes an updated review and analysis in the January issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Opioids vs. placebo, nonopioid alternatives for chronic noncancer pain
An estimated 50 million adults in the United States were living with chronic noncancer pain in 2016 and many of them were prescribed opioid medications, even though a clinical benefit is uncertain.

Probiotic no better than placebo for acute gastroenteritis in children
While probiotics are often used to treat acute gastroenteritis (also known as infectious diarrhea) in children, the latest evidence shows no significant differences in outcomes, compared to a placebo.

Most common shoulder operation is no more beneficial than placebo surgery
In a landmark study published this week in the BMJ, Finnish researchers show that one of the most common surgical procedures in the Western world is probably unnecessary.

Read More: Placebo News and Placebo Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.